Prospective Randomized Studies Comparing Transplants to Conventional Chemotherapy for the Treatment of AML
| Trial (Ref) . | No. of Patients Included (age in yr) . | No. of Patients Planned/Autografted* . | Relapse Incidence4-151 (%) . | LFS4-151 (%; by intention to treat) . | Conclusion in Favor of . |
|---|---|---|---|---|---|
| BGMT‡ (158) | 204 (<45) | 50/39 | 24 56 58 | 67 42 42 | Allo-BMT |
| Hovon (68) | 117 (<60) | 50/32 | 34 60 | 51 35 | Allo-BMT |
| GOELAM (160) | 535 (≤50) | 114/75 | 37 45 55 | 44 44 40 | None |
| EORTC-AML8 (161) | 941 (<45) | 128/95 | 24 41 57 | 55 48 30 | Allo- and Auto-BMT |
| Boston (159) | 94 (<60) | 53/27 | 20 50 | 56 45 | No difference BMT v ABMT |
| POG (64) | 649 (<15) | 219/115 | — 31 58 | — 38 36 | No difference |
| CATALAN Group (157) | 159 (<51) | 68/47 | 23 37 | 31 50 | ABMT |
| MRC 10 (163) | 1966 (<56) | 190/125 | 37 58 | 54 40 | ABMT |
| ECOG (162 and unpublished) | 737 | 115/64 | 33 34 44 | Different by risk groups ABMT always better than CT |
| Trial (Ref) . | No. of Patients Included (age in yr) . | No. of Patients Planned/Autografted* . | Relapse Incidence4-151 (%) . | LFS4-151 (%; by intention to treat) . | Conclusion in Favor of . |
|---|---|---|---|---|---|
| BGMT‡ (158) | 204 (<45) | 50/39 | 24 56 58 | 67 42 42 | Allo-BMT |
| Hovon (68) | 117 (<60) | 50/32 | 34 60 | 51 35 | Allo-BMT |
| GOELAM (160) | 535 (≤50) | 114/75 | 37 45 55 | 44 44 40 | None |
| EORTC-AML8 (161) | 941 (<45) | 128/95 | 24 41 57 | 55 48 30 | Allo- and Auto-BMT |
| Boston (159) | 94 (<60) | 53/27 | 20 50 | 56 45 | No difference BMT v ABMT |
| POG (64) | 649 (<15) | 219/115 | — 31 58 | — 38 36 | No difference |
| CATALAN Group (157) | 159 (<51) | 68/47 | 23 37 | 31 50 | ABMT |
| MRC 10 (163) | 1966 (<56) | 190/125 | 37 58 | 54 40 | ABMT |
| ECOG (162 and unpublished) | 737 | 115/64 | 33 34 44 | Different by risk groups ABMT always better than CT |
*Number of patients randomly assigned to ABMT/number of patients actually autografted (compliance to ABMT).
Rates given in the following order, when applicable: AlloBMT/ABMT/chemotherapy.
This study compares allo-BMT (group 1) with intensive consolidation with or without ABMT (group 2). Evaluation of outcome is from CR and not by intention to treat.